Biohaven Ltd. (BHVN) is a New Haven, Connecticut-based clinical-stage biopharmaceutical company developing therapies across immunology, neuroscience and oncology, including Kv7 ion-channel programs, IgG degraders and antibody-drug conjugates. Shares were trading at $14.16 at midday on Thursday, up 9.77% from the prior close of $12.90, a gain of $1.26 on the session. The direction was unambiguously higher, driven by newly disclosed Phase 1 data for its FGFR3-directed ADC BHV-1530 and confirmation of a cleared regulatory path toward a pivotal trial.
The move centers on BHV-1530, a first-in-class antibody-drug conjugate carrying Biohaven's proprietary TopoIx payload and designed to target FGFR3-driven tumors. Data presented Thursday in a plenary oral session at the 38th EORTC-NCI-AACR Symposium showed that, as of an October 19 cutoff, 30 patients had received monotherapy at doses of 1.0 to 12.0 mg/kg every three weeks, with escalation ongoing.
Among 10 efficacy-evaluable patients with activating FGFR3 alterations treated at 3.3 mg/kg or higher, nine had tumor reduction and six achieved a partial response. Responses appeared in three of five urothelial cancer patients — all of whom had previously progressed on enfortumab vedotin plus pembrolizumab — and in all three HPV-positive head and neck squamous cell carcinoma patients. All responders remained on treatment at the cutoff, several for more than six months. Safety was clean: no dose-limiting toxicities, no treatment-related serious adverse events or deaths, and no cases of hyperphosphatemia, nail dystrophy, serous retinopathy or interstitial lung disease, side effects that commonly constrain approved FGFR inhibitors.
Equally important for valuation, Biohaven said it finished an FDA Type C meeting in the fourth quarter and intends to launch a pivotal study in FGFR3-altered tumors as early as the first half of 2027, beginning in urothelial cancer with an eye toward potential accelerated approval. That converts an early-stage asset into one with a visible regulatory timeline.
The data landed on a stock that had been under pressure. BHVN fell 4.06% on Tuesday and another 2.57% on Wednesday, sliding roughly 18% from its November 11 close of $15.19 and slipping below its 50-day moving average near $13.44. Thursday's rally lifted shares back above that level and through the $13.90-$14.00 area where the prior week's declines had stalled, which likely added momentum from short-term buyers. The shares had roughly 15 million shares sold short, close to three days of average volume, so a squeeze element is plausible alongside the fundamental news. Early trading traced a wide $13.00 to $14.27 band, reflecting a fast repricing rather than orderly accumulation.
Volume was firm but not extreme. Roughly 1.3 million shares had traded by early afternoon against a full-day average in the 2.3 million to 3.2 million range, a pace slightly above normal but far short of a capitulation or blow-off event. The move was also clearly idiosyncratic: the S&P 500 was down about 0.6% and healthcare was among the weakest sectors, while biotech benchmarks such as XBI and IBB gained 0.65% and 0.38% respectively. Peers were mixed, with Praxis Precision Medicines up about 2% and Xenon Pharmaceuticals marginally lower, underscoring that Biohaven's gain was tied to its own readout.
The score runs from 0, meaning no meaningful news and a move that is ordinary for the stock, to 100, meaning transformative news and an extreme, rare price move. Biohaven earns 44 out of 100. The verified news was substantive: Phase 1 response rates, clean safety and a cleared FDA path toward a pivotal study in a program with potential accelerated approval, meaningful for a company with a market value near $2.1 billion. The price reaction was notable but not extraordinary — about 2.3 times the stock's typical daily move of roughly 4.2%, with four larger absolute moves in the past 60 sessions. Strong-but-early news paired with a moderately unusual move produces the mid-range score.
Attention turns back to the late-stage pipeline. The FDA has accepted Biohaven's resubmitted application for Vyglxia (troriluzole) in spinocerebellar ataxia, granted it a user fee goal date in the first quarter of 2027 and scheduled an advisory committee meeting whose date is still to be announced. Execution on BHV-1530 — finalizing the pivotal trial design, opening sites and generating follow-up duration data — is the next proof point, alongside enrollment in the Phase 3 program for BHV-1300 in Graves' disease and the combination cohort with cemiplimab. Fourth-quarter and full-year 2026 results are expected in the first quarter, in line with the company's late-October reporting pattern. Key risks include the small patient numbers behind Thursday's data, the possibility of dilution given ongoing cash burn and a pre-revenue cost base, and regulatory or competitive setbacks that could quickly compress a stock that remains highly sensitive to headline flow.
Tickeron's Trending AI Robots page offers a curated window into the platform's automated trading strategies. Tickeron maintains hundreds of AI trading bots spanning thousands of tickers, but this section surfaces only those posting the strongest performance under current market conditions. Bots differ widely by strategy, timeframe, performance metrics and the symbols they trade, so the lineup shifts as market regimes change. Reviewing the current leaders is a practical way to see how systematic strategies are positioned right now.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
BHVN broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 40 similar instances where the stock broke above the upper band. In 35 of the 40 cases the stock fell afterwards. This puts the odds of success at 88%.
The 10-day RSI Indicator for BHVN moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In 24 of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at 83%.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BHVN as a result. In 82 of 100 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
The Moving Average Convergence Divergence Histogram (MACD) for BHVN turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 35 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BHVN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Aroon Indicator for BHVN entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
BHVN moved above its 50-day moving average on November 19, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for BHVN crossed bullishly above the 50-day moving average on October 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 80%.
Following a +9.57% 3-day Advance, the price is estimated to grow further. Considering data from situations where BHVN advanced for three days, in 201 of 269 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. BHVN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 44 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 98 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: BHVN's P/B Ratio (178.949) is very high in comparison to the industry average of (3.596). P/E Ratio (-3.182) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BHVN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of pharmaceutical drugs
Industry Biotechnology